Total Payments
$975,428
2024 Payments
$122,687
Companies
70
Transactions
1,056
Medicare Patients
25,242
Medicare Billing
$7.1M
Payment Breakdown by Category
Other$610,803 (62.6%)
Research$121,052 (12.4%)
Consulting$119,849 (12.3%)
Travel$94,799 (9.7%)
Food & Beverage$27,697 (2.8%)
Education$1,230 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $555,799 | 218 | 57.0% |
| Unspecified | $121,052 | 10 | 12.4% |
| Consulting Fee | $119,849 | 59 | 12.3% |
| Travel and Lodging | $94,799 | 178 | 9.7% |
| Honoraria | $53,279 | 23 | 5.5% |
| Food and Beverage | $27,697 | 544 | 2.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,725 | 1 | 0.2% |
| Education | $1,230 | 23 | 0.1% |
Payments by Type
General
$854,376
1,046 transactions
Research
$121,052
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $139,615 | 95 | $0 (2024) |
| Janssen Biotech, Inc. | $135,199 | 150 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $130,326 | 161 | $0 (2024) |
| Celgene Corporation | $120,667 | 18 | $0 (2024) |
| Amgen Inc. | $63,622 | 63 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $55,537 | 42 | $0 (2018) |
| Karyopharm Therapeutics Inc. | $54,870 | 44 | $0 (2024) |
| ABBVIE INC. | $47,925 | 51 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $46,791 | 46 | $0 (2023) |
| PFIZER INC. | $26,936 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122,687 | 203 | ABBVIE INC. ($25,413) |
| 2023 | $142,949 | 167 | BeiGene USA, Inc. ($43,667) |
| 2022 | $116,510 | 117 | BeiGene USA, Inc. ($31,051) |
| 2021 | $115,278 | 96 | BeiGene USA, Inc. ($37,837) |
| 2020 | $97,716 | 83 | AstraZeneca Pharmaceuticals LP ($25,652) |
| 2019 | $141,225 | 175 | Janssen Biotech, Inc. ($52,741) |
| 2018 | $178,629 | 160 | Celgene Corporation ($72,379) |
| 2017 | $60,435 | 55 | Celgene Corporation ($33,310) |
All Payment Transactions
1,056 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 12/19/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $32.45 | General |
| Category: Oncology | ||||||
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $65.42 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $6.67 | General |
| Category: Hematology | ||||||
| 11/27/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.17 | General |
| 11/20/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $1,102.50 | General |
| 11/19/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,864.00 | General |
| 11/19/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $644.00 | General |
| 11/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $5.89 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $5,197.63 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,864.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 11/11/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $30.54 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $65,349 | 1 |
| CC-5013-NHL-008 | Celgene Corporation | $33,310 | 1 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $12,849 | 1 |
| Gazyva GA101 Plus Benda CLL | F. Hoffmann-La Roche AG | $3,909 | 2 |
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $3,088 | 2 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $1,436 | 1 |
| An Open-Label Study of Obinutuzumab GA101 Plus Bendamustine in Patients with Previously Untreated Chronic Lymphocytic Leukemia | F. Hoffmann-La Roche AG | $1,082 | 1 |
| A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $27.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 84 | 5,953 | 133,638 | $8.6M | $1.7M |
| 2022 | 96 | 6,423 | 158,639 | $9.8M | $1.8M |
| 2021 | 89 | 6,365 | 119,025 | $8.4M | $1.8M |
| 2020 | 83 | 6,501 | 106,792 | $8.4M | $1.8M |
Total Patients
25,242
Total Services
518,094
Medicare Billing
$7.1M
Procedure Codes
352
All Medicare Procedures & Services
352 procedure records from CMS Medicare Utilization — Page 1 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 12,200 | $1.7M | $508,257 | 30.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 17 | 12,460 | $948,260 | $292,428 | 30.8% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 5,940 | $757,080 | $224,969 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 236 | 742 | $273,056 | $67,758 | 24.8% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 19 | 1,930 | $448,960 | $64,996 | 14.5% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 71 | 185 | $510,970 | $50,154 | 9.8% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 13 | 1,970 | $305,350 | $47,393 | 15.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 209 | 468 | $330,876 | $45,111 | 13.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 75 | 125 | $215,250 | $42,981 | 20.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 31 | 36 | $172,872 | $39,646 | 22.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 2,160 | $141,600 | $39,494 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 291 | 349 | $87,250 | $20,782 | 23.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 17 | 8,345 | $166,900 | $19,750 | 11.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 500 | 1,731 | $34,620 | $14,540 | 42.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 168 | $226,464 | $13,523 | 6.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 435 | 1,227 | $78,528 | $12,683 | 16.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 478 | 1,519 | $54,684 | $11,542 | 21.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 34 | 160 | $11,200 | $11,152 | 99.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $44,667 | $9,844 | 22.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 55 | 60 | $64,020 | $9,815 | 15.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 33 | 20,910 | $104,550 | $8,241 | 7.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 120 | 174 | $54,462 | $8,012 | 14.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 182 | 679 | $73,332 | $7,806 | 10.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 77 | 160 | $55,040 | $7,718 | 14.0% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 22 | 42 | $29,400 | $7,469 | 25.4% |
About Dr. Habte Yimer, M.D
Dr. Habte Yimer, M.D is a Hematology healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881666477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Habte Yimer, M.D has received a total of $975,428 in payments from pharmaceutical and medical device companies, with $122,687 received in 2024. These payments were reported across 1,056 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($555,799).
As a Medicare-enrolled provider, Yimer has provided services to 25,242 Medicare beneficiaries, totaling 518,094 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 352 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Tyler, TX
- Active Since 02/07/2006
- Last Updated 07/08/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1881666477
Products in Payments
- DARZALEX (Biological) $180,502
- BRUKINSA (Drug) $136,615
- CALQUENCE (Drug) $125,772
- Revlimid (Drug) $111,609
- XPOVIO (Drug) $54,870
- NINLARO (Drug) $38,589
- Kyprolis (Drug) $33,869
- EPKINLY (Drug) $32,063
- BLENREP (Biological) $21,362
- Epkinly (Drug) $20,631
- ELREXFIO (Drug) $20,546
- Kyprolis (Biological) $11,436
- ADCETRIS (Biological) $9,238
- GAZYVA (Biological) $7,922
- IMBRUVICA (Drug) $7,078
- Fedratinib (Drug) $6,921
- VENCLEXTA (Drug) $6,653
- Gazyva (Biological) $4,991
- TECVAYLI (Biological) $4,690
- clonoSEQ (Device) $4,145
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.